South Korea Advances Real-World Evidence Integration in Drug Development and Regulatory Decision-Making
核心洞察
South Korea's Ministry of Food and Drug Safety (搜索) has issued new guidelines for using real-world evidence in regulatory decision-making, focusing on clinical trial design and post-market surveillance.
The MFDS (搜索) published the Guideline for Medical Information Database Research in June 2021, emphasizing the use of national health insurance data and electronic medical records for post-marketing safety studies.
The Korea Comprehensive Plan for Drug Safety Management (2020-2024) outlines plans to build a local ecosystem leveraging innovative technology, including real-world evidence, to support new drug development.
South Korea is positioning itself as a regional leader in integrating real-world evidence (RWE) into pharmaceutical development and regulatory processes, with the Ministry of Food and Drug Safety (搜索) (MFDS (搜索)) implementing comprehensive guidelines to support data-driven decision-making in healthcare.
Regulatory Framework Development
The MFDS (搜索) has recently issued guidelines on the use of RWE in regulatory decision-making, with particular emphasis on utilizing real-world data (RWD) to support clinical trial design and post-market surveillance. This regulatory advancement represents a significant shift toward evidence-based approaches that complement traditional randomized controlled trials.
In June 2021, the MFDS (搜索) published the Guideline for Medical Information Database Research, which specifically focuses on utilizing RWE derived from analyzed RWD sources, including national health insurance data and electronic medical records, for post-marketing safety studies. This guideline establishes a framework for leveraging existing healthcare data infrastructure to monitor drug safety and effectiveness in real-world settings.
Strategic National Initiative
The Korea Comprehensive Plan for Drug Safety Management (2020-2024) anticipates that the MFDS (搜索) will continue building a local ecosystem to leverage innovative technology, including RWE, to support new drug development. This strategic plan demonstrates South Korea's commitment to integrating advanced data analytics and real-world evidence into its pharmaceutical development landscape.
The country's regulatory bodies, government organizations, industry and academia leaders, and patient groups have initiated discussions to develop draft guidance for integrating RWE with reimbursement and regulatory decisions, indicating a collaborative approach to policy development.
Healthcare Data Utilization
An increasing number of studies are utilizing healthcare claims databases to generate RWE for the effectiveness and safety of clinical therapeutics in South Korea. These databases provide a rich source of RWD, which can be used to generate RWE for potential risk and benefit assessments derived from sources other than randomized controlled trials.
The utilization of healthcare claims databases represents a significant opportunity to harness existing data infrastructure for pharmaceutical research and development, enabling more comprehensive understanding of drug performance in diverse patient populations.
Comprehensive Approach to Evidence Integration
South Korea's approach encompasses multiple aspects of pharmaceutical development and regulation, including supporting clinical trial design, post-market surveillance, and safety studies. This comprehensive strategy positions the country to leverage RWE across the entire drug development lifecycle, from initial research through post-market monitoring.
The integration of RWE into regulatory and reimbursement decisions represents a paradigm shift that could enhance the efficiency and effectiveness of drug approval processes while ensuring continued safety monitoring in real-world clinical practice.